HF Advisory Group LLC Has $5.71 Million Position in Medtronic PLC $MDT

HF Advisory Group LLC grew its holdings in Medtronic PLC (NYSE:MDT) by 290.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 59,447 shares of the medical technology company’s stock after buying an additional 44,212 shares during the quarter. HF Advisory Group LLC’s holdings in Medtronic were worth $5,710,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Delos Wealth Advisors LLC bought a new position in Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC acquired a new stake in Medtronic during the third quarter valued at approximately $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic in the 4th quarter valued at approximately $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic in the 3rd quarter worth approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Medtronic in the 4th quarter worth approximately $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Down 0.6%

Shares of NYSE MDT opened at $86.13 on Thursday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm’s 50-day simple moving average is $95.05 and its 200 day simple moving average is $96.34. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a market cap of $110.58 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 2.23 and a beta of 0.75.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the firm posted $1.38 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Analysts Set New Price Targets

MDT has been the subject of several recent analyst reports. Leerink Partners reiterated an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. Daiwa Securities Group cut their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Wells Fargo & Company began coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $109.85.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).